Rheumatic Fever Market Research Report Information By Diagnosis (Physical Exam, Blood Test, Electrocardiogram, Other), by Treatment (Pharmacotherapy), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others), by End-User- Forecast Till 2030

Rheumatic Fever Market Scenario

The Rheumatic Fever Market is anticipated to reach USD 1.31 Billion by 2030 at 4.60% CAGR during the forecast period 2022-2030. Rheumatic fever is an autoimmune inflammatory disease which can develop as a complication of inadequately treated strep throat. Strep throat is a condition caused by group a Streptococcus bacterium. Rheumatic fever is common in the age group of 5 to 15 years, but adults can also have the condition. In certain cases, rheumatic fever can cause long-term damage to the heart and heart valves. The increasing occurrences of strep throat and growing prevalence of rheumatic heart disease are expected to be the major drivers for the growth of the market during the forecast period. Moreover, increasing government expenditure for the healthcare sector contributes to the market growth. According to the World Health Organization (WHO) report published in April 2018, approximately 30 million people are affected by rheumatic heart disease globally.

Despite the drivers, lack of awareness about the condition and limited healthcare facilities in emerging economies may hamper the growth of the market during the assessment period.

Segmentation

The global rheumatic fever market has been segmented into diagnosis, treatment, distribution channel, and end-user.

The market on the basis of diagnosis has been segmented into physical exam, blood test, electrocardiogram, and echocardiogram.

The market, by treatment, has been segmented into pharmacotherapy and others. The pharmacotherapy segment is further segmented into antibiotics, anti-inflammatory medication, anticonvulsant medication, and others. Further, the anti-inflammatory medication segment has been segmented into aspirin, naproxen, and others.

The market, by distribution channel, has been segmented into retail pharmacies, hospital pharmacies, and others.

On the basis of end-user, the market has been segmented into hospitals and clinics, diagnostic centers, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rheumatic fever market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European rheumatic fever market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The rheumatic fever market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rheumatic fever market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

Bayer AG, Abbott Laboratories, Johnson & Johnson Services, Inc., F. Hoffman-La Roche Ltd., Novartis AG, Pfizer, Inc., AstraZeneca, Valeant Pharmaceuticals International, Inc., and Eli Lily and Company are some of the key players in the global rheumatic fever market.

Regional Market Summary

Global Rheumatic Fever Market Share (%), by Region, 2017

Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)

Geographically, the Americas is anticipated to dominate the global rheumatic fever market owing to a well-developed healthcare sector, rising prevalence of cardiovascular diseases, and growing healthcare expenditure. According to the Centers for Disease Control and Prevention, approximately 610,000 people die of heart diseases in the US every year. Additionally, increasing awareness among the people regarding the disease and well-developed technology are likely to contribute to the growth of the market.

Europe is expected to hold the second largest position in the global rheumatic fever market. The market growth in this region is attributed to the growing prevalence of rheumatic heart disease, availability of funds for research, and increasing healthcare expenditure.

Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, growing occurrences of rheumatic fever, and increasing government funding for the healthcare sector.

On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle Eastern region due to a well-developed healthcare sector and growing government initiatives for rheumatic heart disease. For instance, according to the RHD Global Status Report, 2015 to 2017, Egypt’s Rheumatic Heart Disease (RHD) programme trained 300 cardiologists and 1,500 primary healthcare physicians in rheumatic heart disease management in 2015. However, the market in the African region is expected to propel owing to the rising prevalence of rheumatic heart disease and increasing government initiatives for the prevention of rheumatic fever.

Global Rheumatic Fever Market, by Diagnosis

• Physical Exam


• Blood Test


• Electrocardiogram


• Echocardiogram

Global Rheumatic Fever Market, by Treatment

• Pharmacotherapy


• Antibiotics


• Anti-inflammatory Medication


• Aspirin


• Naproxen


• Others


• Anticonvulsant Medication


• Others


• Others

Global Rheumatic Fever Market, by Distribution Channel

• Retail Pharmacies


• Hospital Pharmacies


• Others

Global Rheumatic Fever Market, by End-User

• Hospitals and Clinics


• Diagnostic Centers


• Others

Global Rheumatic Fever Market, by Region

• Americas

• North America


• US


• Canada


• South America

• Europe

• Western Europe


• Germany


• France


• Italy


• Spain


• UK


• Rest of Western Europe


• Eastern Europe

• Asia-Pacific

• Japan


• China


• India


• Australia


• South Korea


• Rest of Asia-Pacific

• Middle East & Africa

• Middle East


• Africa

Global Rheumatic Fever Market, by Key Players

• Bayer AG


• Abbott Laboratories


• Johnson & Johnson Services, Inc.


• Hoffmann-La Roche Ltd.


• Novartis AG


• Pfizer, Inc.


• AstraZeneca


• Valeant Pharmaceuticals International, Inc.


• Eli Lily and Company


• Bristol-Myers Squibb Company

Intended Audience

• Pharmaceutical Companies


• Research and Development (R&D) Companies


• Diagnostic Laboratories


• Government Research Institute


• Academic Institutes and Universities